nach oben

Drugs & Aging

Erschienen in:

01.04.2000 | Review Article

Immunosuppression in Older Renal Transplant Patients

verfasst von: Dr Jose M. Morales, Josep M. Campistol, Amado Andrés, Juan C. Herrero

Erschienen in: Drugs & Aging | Ausgabe 4/2000

Einloggen, um Zugang zu erhalten

Abstract

Renal transplantation procedures in patients older than 60 years of age have clearly improved in recent years. In the cyclosporin era, graft and patient survival are good. However, older patients exhibit a higher mortality, especially from infectious and cardiovascular causes, than young patients. In this article we review the immunosuppressive treatment in older patients, analyse what drugs can be used and finally propose several immunosuppressive combinations to treat this group of patients. Currently, new immunosuppressive drugs enable more flexible immunosuppressive protocols. Nevertheless, to avoid overimmunosuppression, elderly patients should be treated with lower doses and fewer immunosuppressive drugs.

Ost L, Lundgren G, Groth CG. Renal transplantation in the older patient. In: Morris PJ, Tilney NL, editors. Progress in transplantation. Edinburgh: Churchill Livingstone, 1984: 1–7

Brunner FP, Fassbinder W, Broyer M, et al. Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial Transplant 1988; 3: 109–22PubMed

Tapson JS, Rodger RSC, Mansy H, et al. Renal replacement therapy in patients over 60 years. Postgrad Med J 1987; 63: 1071–7PubMedCrossRef

Shah B, First MR, Munda R, et al. Current experience with renal transplantation in older patients. Am J Kidney Dis 1988 Dec; 6: 516–23

Morales JM, Muñoz MA, Campo C, et al. Renal transplantation in older patients with double therapy with optional change to cyclosporine monotherapy: long-term results. Transplant Proc 1994 Oct; 26: 2511–2PubMed

Spanish Monotherapy Study Group. Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Transplant Proc 1994 Oct; 26: 2522–4

Lauffer G, Murie JA, Gray D, et al. Renal transplantation in patients over 55 years old. Br J Surg 1988 Oct; 75: 984–7PubMedCrossRef

Felipe C, Miranda B. Caracteristicas del donante cadaver al final de los 90. Nefrologia 1998; 18(5): 7–14

Andreu J, Campistol JM, Oppenheimer F, et al. Improved results in elderly renal transplants without prophylactic steroids. Clin Transpl 1991; 5: 3–6

10.

Morris GE, Jamieson NV, Small J, et al. Cadaveric renal transplantation in elderly recipients: is it worthwhile? Nephrol Dial Transplant 1991; 6: 887–92PubMedCrossRef

11.

Lundgren G, Persson H, Albrechtsen D, et al. Recipient age: an important factor for the outcome of cadaver renal transplantation in patients treated with cyclosporine. Transplant Proc 1999 Feb; 21: 1653–4

12.

Ferham I, Brattstrom C, Durai F, et al. Kidney transplantation in patients between 65 and 75 years of age. Transplant Proc 1989; 21(2): 2018–20

13.

Vivas CA, Hickey DP, Jordan ML, et al. Renal transplantation in patients 65 years old or older. J Urol 1992 Apr; 147: 990–3PubMed

14.

Roza A, Gallagher-Lepak S, Johnson CP, et al. Renal transplantation in patients more than 65 years old. Transplantation 1989; 48: 689–90PubMed

15.

Albrechtsen D, Leivestad T, Sodal G, et al. Kidney transplantation in patients older than 70 years of age. Transplant Proc 1995 Feb; 27: 986–8PubMed

16.

Hestin D, Frimat L, Hubert J, et al. Renal transplantation in patients over sixty years of age. Clin Nephrol 1994; 42: 232–6PubMed

17.

Barry JM, Lemmers MJ, Meyer MM, et al. Cadaver kidney transplantation in patients more than 65 years old. World J Urol 1996; 14: 243–8PubMedCrossRef

18.

Pirsch JD, Stratta RJ, Armbrust MJ, et al. Cadaveric renal transplantation with cyclosporine in patients more than 60 years of age. Transplantation 1989 Feb; 47: 259–61PubMedCrossRef

19.

Schulak JA, Mayes JT, Johnston KH, et al. Kidney transplantation in patients aged sixty years and older. Surgery 1990; 108: 726–33PubMed

20.

Cantarovich D, Baranger T, Tirouvanziam A, et al. One-hundred and five cadaver kidney transplants with cyclosporine in recipients more than 60 years of age. Transplant Proc 1993 Feb; 1: 1323

21.

Tesi RT, Elkhammas EA, Davies EA, et al. Renal transplantation in older age. Lancet 1994; 343: 461–4PubMedCrossRef

22.

Benedetti E, Matas AJ, Hakim N, et al. Renal transplantation for patients 60 years of age or older. Ann Surg 1994 Oct; 220: 445–60PubMedCrossRef

23.

Xenos EX, Ciancio G, Burke GW, et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. Clin Transplant 1997; 11: 497–9PubMed

24.

Campistol JM, Oppenheimer F, Garcia Mena M, et al. Mycophenolate mofetil plus prednisone as induction therapy in suboptimal renal transplantation [abstract]. J Am Soc Nephrol 1998 Sep; 9: 669

25.

Ost L, Groth CG, Lindholm B, et al. Cadaveric renal transplantation in patients of 60 years and above. Transplantation 1980 Nov; 30: 339–40PubMedCrossRef

26.

Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385–95PubMed

27.

Elli A, Rivolta R, Di Palo FQ, et al. A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation: immunosuppressive activity and side effects. Transplantation 1993; 55: 209–12PubMedCrossRef

28.

Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987; 7: 165–77PubMed

29.

European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–5

30.

Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–32PubMedCrossRef

31.

Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–37CrossRef

32.

Vanrenterghem Y, Squifflet JP, Forsythe J, et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. Transplant Proc 1998; 30(4): 1290–1PubMedCrossRef

33.

Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory acute cellular renal transplant rejection. Transplantation 1996; 61: 722–9CrossRef

34.

Weir MR, Anderson L, Fink J, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706–10PubMedCrossRef

35.

Grinyo JM. Mycophenolate: update after it has come of age. Nephrol Dial Transplant 1999; 14: 31–4PubMedCrossRef

36.

Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals or high-fat meals. Transplantation 1995; 59: 505–11PubMed

37.

Kahan BD. Drug therapy: cyclosporine. N Engl J Med 1989; 321: 1725–38PubMedCrossRef

38.

Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977–83PubMedCrossRef

39.

Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Renal Study Group. Transplantation 1997; 64: 436–43PubMedCrossRef

40.

Starzl TE, Fung J, Venkataramanan R, et al. FK506 for liver, kidney and pancreas transplantation. Lancet 1989; I: 100–4

41.

Jordan ML, Shapiro R, Vivas CA, et al. FK506 rescue for resistant rejection of renal allograft under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860–5PubMedCrossRef

42.

Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485–90PubMed

43.

Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105–8PubMed

44.

Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65: 446–9PubMedCrossRef

45.

Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23: 138–47PubMed

46.

Abramovicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–8CrossRef

47.

Pescovitz MD, Book BK, Milgrom ML, et al. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts. Surgery 1994; 116: 811–8PubMed

48.

Shield CF, Edwards EB, Davies DB, et al. Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective multicenter united network for organ sharing study. Transplantation 1997; 63: 1257–63PubMedCrossRef

49.

Shield CF, Cosimi AB, Tolkoff-Rubin N, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979; 28: 461–4PubMed

50.

Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193–8PubMedCrossRef

51.

Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998 Jan; 338: 161–5PubMedCrossRef

52.

Miranda B, Morales JM. Controversias en trasplante renal: trasplante renal y donantes límite [editorial]. Nefrologia 1998; 18(5): 1

53.

Cecka JM, Terasaki PI. Optimal use for older donor kidneys: older recipients. Transplant Proc 1995; 27: 801–2PubMed

54.

Cofán F, Oppenheimer F, Vilardell J, et al. La problemática del receptor mayor que recibe un riñón de un donante mayor. Nefrologia 1998; 18(5): 20–5

55.

Morales JM, Andres A, Pallardo L, et al. Documento de consenso: Trasplante renal en pacientes de edad avanzada con un riñón de un donante añoso. Nefrologia 1998; 18(5): 32–46

56.

Johnson LB, Kuo PC, Dafoe DC, et al. The use of bilateral adult renal allografts: a method to optimize function from donor kidney with suboptimal nephron mass. Transplantation 1996; 61: 1261–3PubMedCrossRef

57.

Andres A, Morales JM, Herrero JC, et al. Double versus single renal allografts from aged donors. Transplantion. In press

Titel: Immunosuppression in Older Renal Transplant Patients
verfasst von: Dr Jose M. Morales
Josep M. Campistol
Amado Andrés
Juan C. Herrero
Publikationsdatum: 01.04.2000
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 4/2000
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200016040-00004

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2000

Diuretic Therapy in Elderly Heart Failure Patients With and Without Left Ventricular Systolic Dysfunction

Tremor-Predominant Parkinson’s Disease

Subcutaneous Hydration By Hypodermoclysis

Clinical Relevance of Hyperhomocysteinaemia in Atherothrombotic Disease

Thrombolytic Therapy in Acute Myocardial Infarction